The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | CEVOLUTION: cevostamab + pomalidomide and dexamethasone in multiple myeloma
Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, discusses the rationale for combining the FcRH5-targeted bispecific antibody cevostamab with pomalidomide and dexamethasone in the Phase III CEVOLUTION trial (NCT07555938). He highlights the high response rates observed with the combination in early studies and its potential role in earlier lines of treatment, while noting that the current trial excludes patients previously treated with BCMA- or GPRC5D-directed therapies. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
